PLURI Aktie

 

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the pricing of a private placement of $3.5 million by long-term shareholder Merchant Adventure Fund, L.P., a major existing shareholder of Pluri, under the same terms as the previously announced investment by Alejandro Weinstein....

HAIFA, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced a $6.5 million strategic private investment (“the Investment”) led by global investor Alejandro Weinstein (the “Investor”), who will join Pluri's Board of Directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo Ltd. (“Kokomodo”), an AgTech company specializing in cultivated cacao production, for $4.5 million payable in the Company's Common Shares (the “Common Shares” and the “Kokomodo Transaction”, respectively). The Investment and the Kokomodo Transaction position Pluri to expand its leadership in sustainable food technologies and strengthen its strategic growth and operational capabilities....

HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (“SR-aGVHD”). This landmark achievement marks a pivotal moment in the advancement of regenerative medicine and highlights the growing clinical and regulatory recognition of MSC therapies' transformative potential....

PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production to a growing number of innovative life science companies PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production to a growing number of innovative life science companies...

December 4, 2024 – TheNewswire - VANCOUVER, BC – Musk Metals Corp. (“Musk Metals” or the “Company”) (CSE: MUSK) (OTC: EMSKF) (FSE: 1I30) is pleased to announce that it has completed its initial outcrop sampling program on its 100% owned Fafnir Lake Uranium and Molybdenum Property, located in the Upper Laurentides region of Quebec.  The Company carried out detailed outcrop sampling in an area roughly 4 km by 1 km encompassing both the Fafnir Lake and Huillier Lake showings which are nearly 3 km apart. Property geology consists of predominantly quartz-feldspar paragneisses intruded by multiple late stage coarse to mostly pegmatitic granite dykes that are sometimes of monzonite composition due to its variable quartz content.  These whitish to pinkish pegmatites are of pluri-metric size and often tens of metres, and can become orange to reddish with increasing hematization.  Intensities of alteration and deformation of paragneisses are generally enhanced with increasing number of intruded pegma...

HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for......

HAIFA, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today announced that the Israel Innovation Authority (“IIA”) will fund Pluri's collaboration with the Bar-Ilan University Research and Development Company Ltd., (“BIRAD”), the commercial arm of Bar-Ilan University, to support the continued development of Placental Mucosal Associated Invariant T (“MAIT”) cells for solid tumors. MAIT cells are known to have unique advantages compared to conventional T-cells but have previously been difficult to expand and scale for clinical investigation and potential commercialization. MAIT cells are believed to be particularly suitable for the treatment of solid tumors, a significant unmet medical need....